US/UK/Canada

Share

Contacts

  • Biotage
    Box 8 751 03 UPPSALA
    +46-18 56 59 00
    +46-18 59 19 22
    http://www.biotage.com
    • Pick a time period -

    Biotage AB (publ) publishes new Financial Goals

    Biotage has two financial goals in its business, an organic sales growth goal of 8 percent and a profitability goal of 15 percent (EBIT).The organic growth goal is now adjusted up to 12 percent and the profitability goal is adjusted up to 25 percent (EBITA) based on the beneficial development of the business.The goals are formulated as an average for rolling three-year periods.This information was submitted for publication, through the agency of the contact persons set out above, at 10.00 CET on March 14, 2022.  Contact persons:Tomas Blomquist, CEOTel: 0705 23 01 63, tomas.

    Biotage Awarded Gold Sustainability Medal by EcoVadis

    We help shape the sustainable science of tomorrow and our future society for the benefit of humankind – HumanKind Unlimited.With this principle Biotage has set out a commitment to unleashing the potential of humanity by working tirelessly to improve the health and wellbeing of both our customers through greener and more efficient solutions, and our own employees through smarter working practices. As part of HumanKind Unlimited comes a commitment to sustainability at every level within Biotage and within every customer relationship.”We have put sustainability at the heart of what we do

    Correction – Biotage and dividend proposal in the Swedish public announcement

    Because of a typo, the board proposal for 2021 dividend is stated as 1 krona and 50 öre in this morning’s Swedish public announcement, correct number is 1 krona and 55 öre in accordance with the full year end report 2021.  This information was submitted for publication, through the agency of the contact persons set out above, at immediate publication on 11 February 2022.  About BiotageBiotage is a Global Impact Tech Company committed to solving society’s problems. We offer workflow solutions and products to customers in drug discovery and development, analytical testing and

    Biotage AB (publ) Year-end report January – December 2021

    Strong growth, both organic and acquired   October–December  · Net sales amounted to SEK 341 (298) million, an increase of 14.5 percent and an organic* growth of 10.0 percent. · The operating profit amounted to SEK 61 (60) million, and adjusted to SEK 70 (60) million. · The operating margin was 18.0 percent (20.0), and adjusted was 20.7 percent (20.0). · EBITA* amounted to SEK 67 (62) million, and adjusted to SEK 76 (62) million. · EBITA margin* was 19.5 percent (20.9) and adjusted was 22.2 percent (20.9). · Profit after tax amounted to SEK 46 (44) million.  ·

    Biotage Launches TurboVap[®] 96 Dual Evaporator

    Uppsala, 25th January 2022, Biotage is pleased to announce the launch of a sophisticated well plate evaporator, the TurboVap® 96 Dual – a second-generation system with two separate, and independently controlled evaporation compartments, building upon the reputable foundation of the Biotage TurboVap® product line. The new TurboVap® 96 Dual has been designed to support enhanced well-plate evaporation within the sample preparation workflow. With its unique two in one functionality users can run the same method on two plates simultaneously, or two independent evaporations, essentially

    Biotage moves to the large cap segment

    As of today January 3, 2022, Biotage is included in Nasdaq Stockholm’s Large Cap segment. The Large Cap segment includes companies with a market capitalization of more than EUR 1 billion.Biotage is a Global Impact Tech Company committed to solving society’s problems. We offer workflow solutions and products to customers in drug discovery and development, analytical testing and water and environmental testing.Biotage is contributing to sustainable science with the goal to make the world healthier, greener and cleaner – HumanKind Unlimited.“Biotage continues to create value for our

    Change in number of shares and votes

    As previously announced, Biotage AB (publ) (“Biotage”) has during December 2021 issued 243,252 new class C shares in accordance with the incentive program LTIP 2021 which was adopted by the Annual General Meeting held on April 28, 2021. Prior to the issue, the total number of outstanding shares and votes in Biotage amounted to 66,227,088 and the total number of votes amounted to 66,008,106.3. Through the issue the number of shares in Biotage has increased by 243,252 shares, corresponding to 24,325.2 votes. As of today, the last trading day of the month, the total number of registered and

    New composition of Biotage Nomination Committee

    Following changes in ownership of Biotage AB, a new Nomination Committee consisting of members appointed by the three largest shareholders or group of shareholders and the Chairman of the Board of Directors has been formed for Biotage AB in accordance with the principles adopted by the annual general meeting held on 28 April 2021. The Nomination Committee shall, before the Annual General Meeting 2022, prepare proposal for the election of Chairman and other members of the Board of Directors, the election of Chairman of the Annual General Meeting, election of Auditors, the determination of

    Issue and re-purchase of class C shares for incentive program

    The Board of Directors of Biotage AB (publ) (“Biotage”) has today resolved, by virtue of the authorisation by the Annual General Meeting held on April 28, 2021, to issue and immediately thereafter re-purchase 243,252 class C shares. The shares are issued and re-purchased in accordance with the incentive program LTIP 2021 which was adopted by the Annual General Meeting held on April 28, 2021. Danske Bank A/S, Danmark, Sverige Filial, will subscribe for the entire issue of new class C shares at a subscription price of SEK 1.39 per share, corresponding to the quota value of the shares. The

    Biotage - Change in number of shares and votes

    As previously announced, Biotage AB (publ) (“Biotage”) has during October 2021 issued 781,991 new ordinary shares in connection with the acquisition of ATDBio Limited.Prior to the issue, the total number of outstanding shares in Biotage amounted to 65,445,097 and the total number of votes amounted to 65,226,115.3. Through the issue the number of shares in Biotage has increased by 781,991 ordinary shares, corresponding to 781,991 votes. As of today, the last trading day of the month, the total number of registered and outstanding shares of Biotage amounts to 66,227,088, whereof 65,983,775

    Biotage AB (publ) Interim report January – September 2021

    Positive development creates opportunities   July–September · Net sales amounted to SEK 305 (263) million, an increase of 16.3 percent and an organic* growth of 17.8 percent. · The operating profit amounted to SEK 68 (61) million.  · The operating margin was 22.3 percent (23.1).  · Profit after tax amounted to SEK 53 (37) million.  · Earnings per share were SEK 0.81 (0.57) before and after dilution. · Cash flow from operations increased to SEK 89 (74) million. · Net cash* as of September 30 amounted to SEK 244 (157) million. · Liquid assets amounted to SEK

    Biotage appoints Nomination Committee

    A Nomination Committee consisting of members appointed by the three largest shareholders or group of shareholders and the Chairman of the Board of Directors has been formed for Biotage AB in accordance with the principles adopted by the annual general meeting held on 28 April 2021. The Nomination Committee shall, before the Annual General Meeting 2022, prepare proposal for the election of Chairman and other members of the Board of Directors, the election of Chairman of the Annual General Meeting, election of Auditors, the determination of fees and matters pertaining thereto. The members

    Biotage acquires ATDBio and strengthens its position in DNA and RNA Oligonucleotide synthesis and purification

    Biotage AB (publ) (“Biotage”) has today entered into an agreement to acquire all outstanding shares in the privately held company ATDBio Limited (“ATDBio”) based in Oxford and Southampton, UK, for a total purchase price of approx. 45 MGBP on a debt free and cash free basis (corresponding to approx. 534.4 MSEK[1]) financed through a combination of a share issue of new ordinary Biotage shares, cash at hand and a revolving credit facility. The transaction closed in connection with the entering into the share purchase agreement. The acquisition of ATDBio adds important platform solutions to

    New capacity helps eliminate bottleneck for COVID-19 vaccines

    Opening a new facility, Biotage triples its production capacity for equipment crucial in the supply chain for the production of mRNA vaccines. Biotage is one of the few companies offering a complete solution and ready to go, off-the-shelf products for the purification of large scale lipids, used in mRNA vaccine development and production. Expanding its production capacity of large-scale flash columns by 300 per cent, Biotage is now helping pharmaceutical companies and contract manufacturers’ scale up lipid production for COVID-19 vaccines. A new, bespoke production facility is now

    Biotage AB (publ) Interim report January – June 2021

    Record quarterly net salesApril–June · Net sales amounted to SEK 303.5 (254.2) million, an increase of 19.4 percent and an organic* growth of 32.1 percent. · The operating profit amounted to SEK 62.5 (24.5) million. · The operating margin was 20.6 percent (9.6).           · Profit after tax amounted to SEK 46.0 (32.2) million. · Earnings per share were SEK 0.71 (0.49) before dilution and SEK 0.70 (0.49) after dilution. · Cash flow from operations increased to SEK 92.3 (57.0) million. · Net cash* as of March 31 amounted to SEK 161.1 (157.0) million. · Liquid assets

    Biotage AB (publ) appoints new CFO

    Maja Nilsson has been appointed as new CFO and member of Biotage AB (publ) Group Management, based out of the Group Headquarters in Uppsala, SwedenMaja brings deep knowledge and experience from different functions within finance and management, in the life science industry. Maja has a solid career in management positions within Getinge, and most currently as CFO for Getinge’s Product Area Critical Care and as Executive Vice President for Maquet Critical Care AB. Prior to joining Getinge, Maja’s most recent assignments was with PwC as Manager and Accounting Consultant and John Mattson

    Berenberg Bank is now covering Biotage AB (publ) (BIOT)

    Biotage is proud to announce that Berenberg Bank now is covering Biotage through their Equity Research – Med Tech & HealthCare Services team.This information was submitted for publication, through the agency of the contact persons set out above, at 11.00 CET on June 29, 2021About BiotageBiotage is a Global Impact Tech Company committed to solving society’s problems. We offer workflow solutions and products to customers in drug discovery and development, analytical testing and water and environmental testing. Biotage is contributing to sustainable science with the goal to make the

    Biotage Launches New Automated Platform for Plasmid DNA Purification

    Biotage is pleased to announce the launch of Biotage[®] PhyPrep, a new automated platform for plasmid DNA purification that releases laboratory staff from the tedium of repetitive, manual labor – and takes full advantage of the PhyTip[®] columns’ dual flow chromatography technology, to yield supercoiled, endotoxin-free, transfection-grade plasmid DNA. Plasmid DNA, or simply plasmids, serve as important tools in life science and biotechnology industry and academic laboratories. Plasmids are commonly used to clone and amplify (make many copies of) or express particular genes. A wide

    Annette Colin has today informed Biotage that she is leaving the position as CFO.

    Annette Colin has a six months’ notice period. The company will now initiate the recruitment of a successor.     This information was submitted for publication, through the agency of the contact persons set out above, at 14.00 CET on May 10, 2021. About BiotageBiotage is a Global Impact Tech Company committed to solving society’s problems. We offer workflow solutions and products to customers in drug discovery and development, analytical testing and water and environmental testing.Biotage is contributing to sustainable science with the goal to make the world healthier, greener

    Resolutions at the Annual General Meeting in Biotage AB on April 28, 2021

    Biotage AB (Reg. No. 556539-3138) today, on April 28, 2021, held its Annual General Meeting. Due to the extraordinary situation as a result of the Covid-19 pandemic, the Annual General Meeting was carried out through advance voting only, without any physical attendance. The Board of Directors’ complete proposals have previously been published and are available at the company’s website, www.biotage.com. Among others, the following resolutions were passed. Appropriation of the company’s resultIn accordance with the proposal by the Board of Directors, the General Meeting resolved on a

    Biotage AB (publ) Interim report January – March 2021

    Double-digit organic growth in two consecutive quartersJanuary - March ·Net sales amounted to 281.4 MSEK (277.3), an increase by 1.4 percent and organically* an increase by 12.0 percent. · Operating profit amounted to 79.4 MSEK (61.4). · The operating margin amounted to 28.2 percent (22.1). · Result after tax amounted to 60.0 MSEK (61.3). · Earnings per share was 0.92 SEK (0.94) before and after dilution. · The cash flow from operating activities increased to 67.6 MSEK (60.8). · Net cash* at March 31 was 189.6 MSEK (157.0). · Cash and cash equivalents amounted to

    NOTICE OF ANNUAL GENERAL MEETING IN BIOTAGE AB (publ)

    The shareholders in Biotage AB (publ), Reg. No. 556539-3138, with its registered office in Uppsala kommun, Uppsala län, are hereby summoned to the Annual General Meeting, to be held on Wednesday, 28 April 2021. In order to mitigate the spread of Covid-19, the Board of Directors has decided that the Annual General Meeting will be conducted by advance voting only, without physical presence of shareholders, proxies and third parties. Biotage welcomes all shareholders to exercise their voting rights at this Annual General Meeting through advance voting on the basis of temporary statutory

    Biotage AB (publ) publishes its 2020 Annual Report, Corporate Governance Report and Remuneration Report

    Biotage’s 2020 Annual Report, Corporate Governance Report and Remuneration Report are as of today available at: www.biotage.com This is information that Biotage AB (publ) is obliged to make public pursuant to the Securities Markets Act.  The information was submitted for publication at 17.00 CET on March 26, 2021.Contact persons:Tomas Blomquist, CEOTel: 0705 23 01 63, tomas.blomquist@biotage.comBiotage ABBox 8SE-751 03 UppsalaTel:018 56 59 00 www.biotage.com    About Biotagesolutions and products to customers in drug discovery and development, analytical testing and

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe